BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3371
- Registration Number
- NCT00812175
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Phase 3
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- Drug: Riociguat (Adempas, BAY63-2521)Drug: Placebo
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 445
- Registration Number
- NCT00810693
- Locations
- π¦πΊ
Royal Hobart Hospital, Hobart, Tasmania, Australia
Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens
Phase 2
Completed
- Conditions
- Ovulation Inhibition
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)Drug: EV/DNG (SH T00658L)
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 209
- Registration Number
- NCT00805415
- Locations
- π³π±
Dinox B.V., Groningen, Netherlands
π©πͺDinox GmbH Berlin, Berlin, Germany
Scandinavian Mirena Insertion Nulliparous Trial.
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 224
- Registration Number
- NCT00798980
INSIGHT - Post Marketing Surveillance
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 791
- Registration Number
- NCT00792350
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Ovarian Neoplasms
- Interventions
- Drug: Sorafenib (Nexavar, BAY43-9006)Drug: Placebo
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 246
- Registration Number
- NCT00791778
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Completed
- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Interventions
- Drug: Interferon beta-1b (Betaseron, BAY86-5046)
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1723
- Registration Number
- NCT00787657
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
Phase 2
Completed
- Conditions
- Venous ThrombosisDeep Vein Thrombosis
- Interventions
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT00786422
Post Marketing Surveillance Study on Emselex After Launch in Germany
Completed
- Conditions
- Overactive Bladder
- Interventions
- Drug: Darifenacin, Emselex (BAY79-4998)
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2010-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5821
- Registration Number
- NCT00786448
Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 236
- Registration Number
- NCT00786253
Β© Copyright 2025. All Rights Reserved by MedPath